496863-95-7Relevant academic research and scientific papers
Polycyclic compound and its pharmaceutical composition and application
-
Paragraph 0228; 0229; 0230; 0230; 0231; 0232, (2018/03/26)
The invention discloses a polycyclic compound and its preparation method, pharmaceutical composition and application. The polycyclic compound (I) and its isomer, prodrug, stable isotope derivative ora pharmaceutically acceptable salt have the structure shown in the description. The polycyclic compound has good IDO1 inhibitory effects and can be used for effectively treating, alleviating and/or preventing various related diseases such as tumors and infectious diseases caused by immunosuppression.
Pyrrolopyrazines as kinase inhibitors
-
Page 7, (2010/02/05)
The invention relates to pyrrolo [2,3b]-pyrazine derivatives having the general formula (I) : ???wherein :R2 and R3 are identical or different and represent H, C1-C6 alkyl, said alkyl being a straight or branched-chain alkyl, which can be substituted,R6 i
Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects
Mettey, Yvette,Gompel, Marie,Thomas, Virginie,Garnier, Matthieu,Leost, Maryse,Ceballos-Picot, Irène,Noble, Martin,Endicott, Jane,Vierfond, Jean-Michel,Meijer, Laurent
, p. 222 - 236 (2007/10/03)
Cyclin-dependent kinases (CDKs) regulate the cell cycle, apoptosis, neuronal functions, transcription, and exocytosis. The observation of CDK deregulations in various pathological situations suggests that CDK inhibitors may have a therapeutic value. In th
